Loading
CI
Conformis Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 May 2021.
Conformis Inc: what insiders have been doing
Every trade that managers of Conformis Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Conformis Inc has had no insider filing for more than a year; the last one goes back to 5 September 2023.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
42
Thresholds
n/a
Buy Volume
€15,233
1 ops. · all time
Sell Volume
€208,899
19 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$53.4M
Gross profitUS$20M37% margin
Net income-US$43.5M-81.3% margin
Last declaration on 5 September 2023
Declarations42 total
10,470 sharesCommon StockSEC:0001140361-23-042503:0
20,320 sharesCommon StockSEC:0001140361-23-042496:0
19,909 sharesCommon StockSEC:0001140361-23-042499:0
18,000 sharesCommon StockSEC:0001140361-23-042502:0
81,465 sharesCommon StockSEC:0001140361-23-042501:0
19,273 sharesCommon StockSEC:0001140361-23-042497:0
18,379 sharesCommon StockSEC:0001140361-23-042498:0
190,277 sharesCommon StockSEC:0001140361-23-042500:1
17,778 shares0Common StockSEC:0001140361-23-042500:0
75,150 shares0Common StockSEC:0001305773-23-000025:0
75,150 shares0Common StockSEC:0001305773-23-000024:0
130,870 shares0Common StockSEC:0001305773-22-000073:0
130,870 shares0Common StockSEC:0001305773-22-000068:0
261,740 shares0Common StockSEC:0001305773-22-000066:0
130,870 shares0Common StockSEC:0001305773-22-000072:0
130,870 shares0Common StockSEC:0001305773-22-000065:0
130,870 shares0Common StockSEC:0001305773-22-000074:0
304,615 shares0Common StockSEC:0001305773-22-000069:0
130,870 shares0Common StockSEC:0001305773-22-000070:0
130,870 shares0Common StockSEC:0001305773-22-000071:0
22,396 shares@ US$0.4597.1% of flowCommon StockSEC:0001305773-22-000061:0
450,000 shares0Common StockSEC:0001305773-22-000037:0
19,000 shares@ US$1.946100.0% of flowCommon StockSEC:0001305773-22-000023:0
11,537 shares@ US$0.651357.0% of flowCommon StockSEC:0001305773-22-000009:0
25,249 shares@ US$0.744512.0% of flowCommon StockSEC:0001305773-22-000004:0
25 of 42 declarations
About Conformis Inc
Conformis Inc. (ticker: CFMS) is a U.S. medical technology company listed on NASDAQ in the United States. Founded in 2004, the company built its identity around a proprietary patient-specific orthopedics model centered on its iFit Image-to-Implant platform, which uses imaging data to design, manufacture, and commercialize implants tailored to each patient’s anatomy. Its operations have historically been based in the Boston, Massachusetts area, including facilities in Billerica, and the company has developed integrated capabilities across design, manufacturing, and commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305773/000130577318000016/cfms-123117x10k.htm?utm_source=openai))
Conformis’ core business is personalized joint replacement, with a primary focus on the knee and a secondary presence in hip arthroplasty. Its product history includes the iUni, iDuo, iTotal CR, iTotal PS, and the Conformis Hip System. The company’s proposition is to provide individually sized implants and associated surgical instrumentation intended to improve anatomic fit, operating-room workflow, and potentially clinical outcomes. In competitive terms, Conformis operates in a market dominated by large global orthopedics players, so its positioning is that of a differentiated specialty medtech company rather than a scale leader. Its competitive edge has historically depended more on product innovation, intellectual property, and surgeon adoption than on broad manufacturing scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305773/000130577318000016/cfms-123117x10k.htm?utm_source=openai))
Read moreShow less
The company was incorporated in 2004 and moved into commercial operations during the following years, introducing its first products in 2007 and later rolling out successive generations of knee systems before adding hip. SEC filings also show that Conformis financed growth through multiple private rounds before its IPO in July 2015. That history is important for investors because it reflects a medtech business with meaningful R&D intensity and a long development-to-commercialization cycle, often requiring outside capital to support growth, manufacturing scale-up, and market expansion. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305773/000130577318000016/cfms-123117x10k.htm?utm_source=openai))
Geographically, Conformis has pursued commercial reach beyond the U.S., including a European presence, while maintaining its main operational base in the United States. The company has also emphasized its patent portfolio and proprietary know-how as strategic assets. In terms of recent context, the publicly available sources reviewed confirm ongoing SEC reporting activity and insider-transaction filings around CFMS, which is consistent with a listed issuer subject to regular disclosure. For French-speaking investors, Conformis should be viewed as a niche small-cap medtech name with technology-driven differentiation, but also with execution risk tied to clinical adoption, reimbursement dynamics, and competition from much larger orthopedic groups. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305773/000130577323000013/cfms-20221231.htm?utm_source=openai))
